A business profile of NeuroMetrix is available at: http://www.kidela.com/members/neurometrix45/About NeuroMetrix NeuroMetrix is an innovative medical device company that develops and markets home use and point-of-care devices, associated consumables, and support software for the treatment and management of diabetes and its complications. The company is focused on nerve related complications of diabetes, called diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation, cause disabling chronic pain, and increase the risk of falling in the elderly. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company’s products are used by physicians and other clinicians, in retail health settings such as pharmacies, and by managed care organizations to optimize patient care and reduce healthcare costs. The company markets the NC-stat ® DPNCheck ™ device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. The company is in late stage development of SENSUS ™, a pain management device. The company has additional therapeutic products in its pipeline. For more information, please visit http://www.neurometrix.com.
NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com, a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, reported today that its Chief Medical Officer was interviewed by KIDELA TV, a financial news network. The interview is available at: http://www.youtube.com/watch?v=6xY0jmYk44M&feature=youtu.be In the interview, Dr. Snow discusses some of the complications of diabetes including diabetic peripheral neuropathy or DPN. DPN is the most common chronic complication of diabetes affecting over 50% of people with diabetes. It can lead to costly and debilitating foot ulcers and, ultimately, to amputation. Early detection provides the opportunity for clinical intervention and behavior modification which may moderate the effects of DPN. NeuroMetrix markets a medical device, NC-stat ® DPNCheck ™, which provides a fast, accurate, quantitative and cost effective test for the early detection of systemic neuropathies, such as DPN. Dr. Snow, a practicing endocrinologist, notes that NC-stat DPNCheck is a significant advance over the tools historically available for detection of DPN. These tools include the monofilament and the tuning fork which detect DPN only at a late stage where a patient may already have lost protective sensation in his feet. Dr. Snow also comments on the correlation between DPN and risk of cardiac disease, as well as on the benefits in reinforcing patient compliance. Dr. Snow has extensive experience in the field of diabetes, including patient care and clinical research. Prior to joining NeuroMetrix, he spent the 17 years at the Joslin Diabetes Center in Boston, MA which is affiliated with Harvard Medical School and is considered the world's oldest and most respected diabetes care facility. Most recently, Dr. Snow was Director of Medical Programs at the Joslin Center for Strategic Initiatives and previously was Acting Chief of the Adult Diabetes Section at the Joslin. Dr. Snow also holds an appointment as Assistant Professor of Medicine at Harvard Medical School.